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Abstract
Background-An implantable cardio-
verter defibrillator (ICD)maybe effective
in reducing the risk of sudden cardiac
death. The high cost of ICD treatment,
however, compared with alternatives
raises the question of whether this new
technology is an efficient use of scarce
health care resources.
Objective-To estimate the incremen-
tal cost effectiveness of the implantable
cardioverter defibrillator compared with
drug treatment with amiodarone in the
management of patients at high risk of
sudden cardiac death.
Design-A cost effectiveness model was
constructed from data already published
and other secondary sources. Differences
in patient survival were calculated from
life tables for comparable ICD and
amiodarone patient series. Costs were
based on typical patient management
protocols derived from current United
Kingdom practice and interviews with
physicians.
Main outcome measures-Cost effect-
iveness of ICD treatment was computed
over 20 years; all future costs and effects
were discounted at 6% per year.
Results-Estimated life expectancy
was 111 and 6-7 years with ICD and
amiodarone respectively; the discounted
20 year difference lies in the range 1P7 to
3*7 years. Discounted 20 year treatment
costs were £28 400 for the ICD and £2300
for amiodarone. Cost effectiveness ofICD
treatment lies in the range of £15 400 to
£8200 per life-year gained.
Conclusions-Cost effectiveness ofICD
treatment is similar to some existing
cardiac programmes funded under the
NHS but uncertainty exists due to
limitations of the data. Costs of ICD
treatment may fall in the future as the
life of the device increases and less
invasive implantation methods are
needed. The effectivess of ICD compared
with amiodarone is currently being
studied by a randomised controlled trial.
(Br Heart J 1992;68:241-5)
The implantable cardioverter defibrillator
(ICD) was first implanted into a human
patient in 1980' and since then it has gained
wider use in the management of patients at
risk of sudden cardiac death due to ventricular
tachycardia (VT) or ventricular fibrillation
(VF). In 1990 there were estimated to be over
4000 new implants in the United States2
whereas the total in the United Kingdom in
January 1990 was reported to be 49 devices
implanted into 40 patients.'
The ICD is an electronic device designed to
monitor the heartbeat, recognise VT or VF,
and deliver an electric shock (up to 40 joules)
to stop the life threatening arrhythmia.
Within the generic classification of ICD there
are various types, but all consist of a battery
powered pulse generator that is implanted in a
subcutaneous abdominal pocket and capable
of delivering shocks to the heart through two
or three electrodes that may be inside or
outside the heart.
Use of an ICD is generally considered in
patients at high risk of VT, VF and sudden
cardiac death, specifically in survivors of sud-
den cardiac death where electrophysiological
study, treadmill, and holter study have failed
to identify an effective antiarrhythmic drug. In
such patients the main therapeutic alternatives
are (a) to implant an ICD that will terminate
arrhythmias when they occur; (b) surgical
management such as endocardial resection
where an attempt is made to remedy the cause
of the arrhythmias; (c) empirical drug treat-
ment with amiodarone where the goal is to
prevent arrhythmias occurring.
In this study we compare the costs and
effects of treatment with ICD versus the alter-
native amiodarone. Although these are not the
only comparisons that could be made they are
relevant comparisons that are prevalent in
studies examining ICD efficacy.4 The
relevance of this comparison is also supported
by the existence of a large continuing
Canadian randomised controlled trial of
amiodarone versus ICD treatment.6
As well as the improved efficacy of ICD
management is the expectation of higher
costs, with the device alone costing about
11 000. Economic evaluation is therefore a
necessary and important feature of any overall
assessment of this new medical technology: to
what extent is ICD treatment a cost-effective
addition to the management of patients at risk
of sudden death and how does it compare with
other cardiac procedures that are competing
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for scarce health care resources? This study is
a preliminary assessment of the economics of
ICD treatment in the United Kingdom in
which we use the limited published data
available to estimate cost effectiveness under
various possible outcomes of ICD technology
in the near future.
Patients and methods
MORTALITY
No randomised controlled trial of amiodarone
versus ICD treatment for patients at high risk
ofVT or VF has yet been reported. Among the
assessments of ICD efficacy, two studies have
compared the device with amiodarone.
Fogoros et al analysed a series of78 consecutive
patients who were eligible for ICD, a third of
whom did not receive the device because of
temporary unavailability.4 Although this
natural experiment was suggestive of a con-
siderable mortality benefit from ICD compared
with amiodarone the results are atypical
because the sudden death rate of31% in the 29
patients taking amiodarone was three times
higher than the 9% sudden death rate reported
in the largest published series of 462 patients
taking this drug.7 Also a case control study,
which is reported in abstract, of ICD versus
drug treatment is indicative of ICD mortality
benefit, but this is of limited value for the
present comparison because only 43% of con-
trol patients received amiodarone.
In the absence of reliable data on relative
efficacy from a clinical experiment of
amiodarone versus ICD, outcomes for our
study of cost effectiveness are based upon the
largest published patient series for each treat-
ment. Data on survival after ICD implantation
were taken from the follow up study of 270
patients by Winkle et al8 in the United States.
In this consecutive patient series the mean age
was 58 (range 12 to 77) and 80% were men.
There was a history of sustained ventricular
tachycardia or fibrillation in 96% of patients
and 80% had experienced one or more earlier
cardiac arrests. Two hundred and sixty nine
patients (96%) had experienced at least one
failure of antiarrhythmic drug either clinically
or at an electrophysiological study, and the
average number of drug failures was 3-4 for the
entire group.
Data on survival with amiodarone treatment
were taken from the follow up study of 462
patients by Herre et al.7 The mean age in this
consecutive patient series was 61 and 80% were
men. Patients were eligible for amiodarone
treatment if they had documented sustained
ventricular tachycardia or had experienced
cardiac arrest. Before initiation of amiodarone
treatment, all patients had experienced failure
of at least one antiarrhythmic drug either
clinically or at electrophysiological study, and
on average there were 2-4 drug failures. These
characteristics suggest that many of the
patients in the amiodarone series would have
been eligible for ICD implantation.
LIFE EXPECTANCY
An assumption ofour analysis was that differen-
tial patient life expectancy between the treat-
ment groups would be largely a function of
differences in rates of sudden cardiac death,
because neither treatment is presumed to
reduce deaths other than sudden cardiac
deaths. Therefore, compared with the
amiodarone series, the lower rate of other
deaths reported in the ICD series suggests that
one or more unknown prognostic factors are
unequally distributed between the groups.7 We
have attempted to compensate for this bias by
calculating life expectancies with an adjusted
all cause mortality where both treatment
groups were assumed to have the same non-
sudden death rate, this being arbitrarily set to
the mean of the non-sudden death rates for the
two groups combined for each follow up time.
Also for comparison, all life expectancy and
cost effectiveness estimates are made with the
unadjusted all cause mortality from the
published series.
Patient life expectancy is calculated from the
adjusted and unadjusted five year mortality
series for both treatments by the declining
exponential approximation to life expectancy
(DEALE) method proposed by Beck et al.9
This method permits declining exponential
survival models to be estimated for each five
year mortality series, thus enabling forward
projections to calculate life expectancies. The
DEALE method has been used in previous
cardiac studies and the main assumption of the
method is that life expectancy approximates to
the reciprocal of the annual mortality.'0
COSTS
For items such as the ICD device and prescrip-
tion drugs, costs can be based on market prices,
but limited data are available on the costs of
non-marketed health care items such as ICD
implantation surgery; NHS accounting sys-
tems do not generate information in a form that
can easily be used for the routine costing of
specific interventions. Ideally, a detailed prosp-
ective costing study of antiarrhythmic treat-
ment would be undertaken, as was done with
heart transplantation in the United Kingdom."
But the reliability of this method applied to
ICD treatment in the United Kingdom might
be suspect for two reasons: the small numbers
ofpatients who have received ICDs (49 devices
in 40 patients by January 19903) and the rapid
changes in ICD technology.
The approach used by us is to combine costs
and published data with information from
physician interviews to build protocols of
resources used for typical ICD and amiodarone
patient management in the United Kingdom.
Table 1 summarises these protocols. They
were costed by two main sources of data: (a)
national published data on hospital costs and
outpatient visits; (b) published data from a
recent detailed study of costs ofvarious types of
cardiac surgery.'2
The most common method of ICD implan-
tation, left lateral thoracotomy,38 was judged to
be between a planned coronary artery bypass
graft and an adult closed heart procedure in
terms of resource use. It was costed at £3000
exclusive of device generator (,£9500) plus
leads and patches (,C1200). Replacement of the
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Table 1 Typical patient management protocols for ICD and amiodarone treatment
ICD treatment Amiodarone treatment
Initial treatment
In hospital 1 day intensive care unit, 7-11 days on ward 1 week on ward
Main materials ICD generator, leads, patches Amiodarone
Main procedures Surgical implantation (lateral thoracotomy); EP study to Further electrophysiological evaluation
test device after implantation
Routine follow up
Hospital visits Outpatient visit every 3 months; 1 inpatient day every 4 Outpatient visits every 3 months
years to replace generator
Main materials Device generator replaced every 4 years Amiodarone (oral) daily (400 mg)
Main procedures Device interrogation and battery checking (outpatient); Tests to monitor for drug toxicity
device replacement under general anaesthetic (inpatient)
ICD generator, on average every four years,
was costed as equivalent to a pacemaker
replacement (,C750)'" and added to this are the
costs of routine three-monthly follow ups for
device and battery checks.
Consistent with the patient series of Winkle
et al it was assumed that 23% of patients with
an ICD would also be taking amiodarone.
Patients receiving only amiodarone were
assumed to spend one week in hospital for a
loading dose of the drug and further EP
evaluation (L1050) then an oral daily dose of
400 mg in each subsequent year (1223 per
year) with outpatient visits to monitor for
toxicity every three months (L80 per year).
Given limitations ofthe data the cost analysis
contains several simplifying assumptions. For
example, no explicit additional costs are incor-
porated into the amiodarone treatment group
for management of recurrence of arrhythmia,
drug intolerance, or discontinuation of the
drug. These costs will be at least partly offset by
additional costs in the ICD group for the
management of complications such as infec-
tions and false shocks.
COST EFFECTIVENESS
The purpose ofthe analysis ofcost effectiveness
is to determine at what extra cost the extra life-
years ofpatient benefit result from ICD implan-
tation. All analyses are relative to the alter-
native of amiodarone treatment, and therefore
the cost effectiveness of ICD treatment is the
ratio of the net cost of ICD treatment (ICD
total costs minus amiodarone total costs) to the
net benefits measured as life-years gained (or
lost).
Giventhat costs andbenefitsoccurat different
times in the future it is necessary to discount
the future trends into present values. The need
to discount in economic appraisal merely
reflects the fact that individuals have a positive
rate of time preference and prefer benefits
sooner and costs later.'3 The discount rate used
is 6% per annum as recommended by Her
Majesty's Treasury for public sector
appraisals.
Sensitivity analysis was performed on
several variables where limited data were
available and uncertainty exists. The purpose
of sensitivity analysis is to explore the extent to
which the estimated cost effectiveness results
stand up to alternative estimates and assump-
tions conerning key variables. We conducted a
two way analysis of sensitivity: (a) by mortality
series, adjusted versus unadjusted; (b) by alter-
native assumptions about future treatment and
costs. Whereas some alternative assumptions
are based on present trends in management (for
example reduced follow up times and increased
generator life) others, such as the possible
reduction in the price of the device due to
increased market competition, are more
speculative.
Results
Table 2 shows the five year mortality data for
ICD and amiodarone treatment. At five years
the sudden and non-sudden death rates for
ICD treatment were 4-4% and 21-8% respec-
tively, with comparative amiodarone death
rates of 21% and 41%. Adjusted all cause five
year mortality for ICD treatment was
estimated to be 35-8% (this being 4-4 + ((21-8
+ 41.0)/2)) and 52-4% for amiodarone.
In table 3 life expectancy with ICD is
estimated for the adjusted mortality series to be
11 1 years and 6-7 years with amiodarone. The
difference in life expectancies discounted at 6%
is 2-3 years in favour of ICD. Overall, in the 20
year period ofthe projected costs and benefits of
the study, a range of 1-7 to 3-7 discounted life
years would be gained from ICD treatment.
Table 4 shows total cost and cost effectiveness
data. For the adjusted mortality series the total
discounted cost ofICD treatment over 20 years
is £28 400 compared with £2300 for amio-
Table 2 Mortality data for ICD and amiodarone treatment
ICD treatment (Winkle et al,' n = 270)/amiodarone treatment (Herre et al,' n = 462)
Mean % Adjusted
Follow up % Sudden % Non-sudden % All cause % Non-sudden all cause
year deaths deaths deaths deaths* deaths
1 09/ 90 6-8/15-0 7-7/24.0 10-9 11.8/19.9
3 4-4/15-0 14-0/28-0 18-4/43-0 21-0 25 4/36-0
5 4-4/21-0 21 8/41-0 26 2/62.0 31-4 35 8/52 4
*The mean non-sudden death rate for the two groups combined at each follow up time is added to the sudden death rate to derive
the adjusted all cause death rate.
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Table 3 Declining exponential approximation of life expectancy and discounted life-years gainedfrom ICD treatment
Adjusted mortality Unadjusted mortality
ICD Amiodarone ICD Amiodarone
Mean annual mortality rate (m) 0 09 0-15 0-06 0-19
Life expectancy (1/m) 11 10 6-67 16-60 5 30
Life expectancy discounted at 6% per year 7 9 5-6 10 1 4-2
Total discounted life-years gained from ICD 2-3 - 59 -
Discounted life-years gained from ICD in 20 years 1-7 - 3-7
For the adjusted ICD mortality series the cumulative proportion surviving, S(t), to t = 5 years (0-64 from table 2) is determined
by S(t) = exp(-mt) where m = 009 and t = 5.
darone, giving a net cost of £26 100 for ICD
treatment. Taking the ratio of the net cost of
ICD treatment to the net benefit (1I7 discoun-
ted life-years) gives the cost effectiveness of
ICD therapy as £15 400 per life-year gained.
The same calculations for the unadjusted
survival series show amuch lower cost effective-
ness ratio of £8200 per life-year gained.
The sensitivity analysis in table 5 shows that
cost effectiveness calculations aremost sensitive
to alternative estimates of patient survival,
being £15 400 per life year gained for the
mortality series adjusted for between study
differences in non-sudden death rates and
£8200 for the unadjusted mortality data.
Analysis by alternative treatment assumptions
for each mortality series suggests that reduc-
tions in the fixed "start up" costs of treatment
due to initial ICD implantation will generate a
modest improvement in cost effectiveness
(£14 590 per life-year, adjusted series) when
compared with reductions in recurrent cost due
to factors such as increased life expectancy of
the device from four to six years (£12 297 per
life-year).
Discussion
In a recent editorial Campbell concluded that
the implantable defibrillator is an effective treat-
ment for those at risk of sudden cardiac death
and that cost is the main constraint upon the
wider use of this treatment in the United
Kingdom.'4 Cost effectiveness analysis offers a
standardised framework for assessing and com-
bining costs and effects to permit comparison
Table 4 Costs, effects, and cost-effectiveness ofICD treatment
Adjusted mortality Unadjusted mortality
Total discounted cost to 20 years:
ICD treatment C28 400 £32 300
Amiodarone treatment £2300 £2100
Net cost of ICD treatment £26 100 £30 200
Net effectiveness of ICD 1-7 life-years 3-7 life-years
Net cost effectiveness of ICD £15 400 per LYG £8200 per LYG
Cost effectiveness is calculated as the ratio of net cost to net effectiveness for each mortality series.
LYG, life-years gained.
Table 5 Sensitivity analysis of cost effectiveness estimates
Cost per life-yeargained (£)
Adjusted Unadjusted
mortality mortality
Base estimate 15 400 8200
Cost of ICD implantation surgery reduced by 50% to £1500 14 590 7769
Device generator price reduced by 20% to £7600 13 029 6890
Average generator life increased from 4 to 6 years 12 297 6384
Follow up frequency reduced from 3 monthly to 6 monthly 14 776 7784
Amiodarone management costs increased by £1000 per year 12 954 7221
between new and existing treatments compet-
ing for limited resources.
Our study shows that, compared with
management with amiodarone, the cost effect-
iveness of ICD treatment lies in the range
£8200 to £15 400 per life-year gained. How
should such cost effectiveness data be inter-
preted? A common and illuminating approach
is to compare the results from this study with
other cardiac treatment interventions to find
out whether the cost per unit outcome from
ICD treatment is greater or less than other
treatments that are funded through the NHS.
Whereas some cardiac interventions such as
heart transplantation generate life-years at
lower cost than ICDs (£5000 per quality adjus-
ted life year, 1985 prices) some interventions
are nearly equivalent or worse than ICD treat-
ment, such as coronary bypass grafting for
moderate angina with one vessel disease
(£12 000 per quality adjusted life-year)'5 and
drug treatment (in addition to diet) for lower-
ing blood cholesterol to reduce coronary mor-
tality (£19 000 per quality adjusted life year).'6
Sensitivity analysis indicates that the main
source ofvariation in estimates ofcost effective-
ness relates to uncertainty about the size of the
mortality benefit attributable to ICD treatment.
In our study this uncertainty is due, in part, to
questions of comparability of the ICD and
amiodarone series and the extent to which the
mortality data can be generalised to other
patient groups. For example, recent smaller
series have reported somewhat higher survival
with amiodarone,17 '8 and with ICD.'9 Eco-
nomic evaluation ultimately depends on the
strength of the epidemiological evidence on
which it is based, and for this reason more
precise estimates of size of the effects of ICD
treatment from randomised controlled trials, or
(at least) well organised registries,' would be
valuable.
Present estimates of cost should be viewed in
the context of the rapid technological innova-
tion surrounding the ICD device and its
implantation. Such problems are commonplace
in assessments of new technologies.2' At least,
evaluation studies should be designed to recog-
nise the dynamic nature of the technology and
attempt to quantify the impact of possible
future trends in a sensitivity analysis. In the
specific case of ICDs there are three reasons
why costs of ICD treatment are likely to fall in
the future:
(a) The next generation of ICD devices are
expected to have much longer lives (possibly up
to nine years) and have capacitors that reform
automatically thus reducing the need for
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frequent maintenance or device replacement;
(b) Advances in methods for implanting
defibrillators may result in current surgical
techniques of lateral thoracotomy and median
sternotomy being superseded by less invasive
transvenous methods with an expectation of
lower costs and risks;
(c) More widespread use of the devices and
variation in device types may serve to promote
price competition between manufacturers.
The validity of the estimates presented in our
study is difficult to determine. One approach is
to examine the extent to which our estimates
are consistent or convergent with other studies.
In a recent study in the United States Kupper-
man et al22 estimated a cost effectiveness range
for ICD versus drug treatment of US$15 600
to $29 600 per life-year gained, deriving cost
data primarily from 1984 Medicare claims and
survival estimates from publications before the
major reports used here. An Australian tech-
nology assessment report on ICDs has also
appeared and ICD cost effectiveness is
estimated to range from AU$17 850 to
AU$35 800 per life year, where ICD is
assumed to be used only after electrophysio-
logical testing has failed to find an effective
antiarrhythmic agent.23 Results from our study
are therefore consistent with other published
studies and very similar in estimates of cost
effectiveness.
A limitation of existing economic appraisals
is the exclusion of effects that antiarrhythmic
treatments may have upon patients' health
related quality of life. To measure treatment
benefits only in terms of life extension is to bias
comparison against those treatments that have
higher mortality but may maintain or improve
quality of life, either through the relief of
symptoms or the avoidance of adverse effects.
Some follow up studies on ICD patients have
explored physical and psychological effects but
no prospective controlled comparative studies
have yet been published.2'26 Quality of life
data, however, are being collected as part of the
Canadian implantable defibrillator study6 (a
randomised controlled trial of ICD versus
amiodarone) with a variety of measures includ-
ing the Nottingham Health Profile27 and the
Mental Health Inventory28 to assess psy-
chological wellbeing.
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